Georgia State Researcher Gets $3.4 Million Grant to Develop Vaccine Technology Against Flu, RSV
News Feb 01, 2013
The grant from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases will aid Kang’s research in developing a virus-like particle, or VLP, vaccine technology.
VLPs mimic viruses, but are non-infectious, which allows for safer vaccines, especially for young children, elderly people and patients whose immune systems are compromised. VLPs trigger the immune system to respond, leading to immunity in the same way that regular vaccines made with whole viruses act.
“VLPs are a result of new technology using recombinant genetic engineering,” Kang said. “VLP technology can manipulate pathogens in a safe way so that we can design a vaccine mimicking the shape and structure of a virus.
“A VLP is an empty particle without the genetic information of a pathogen, thus highlighting its safety.”
The potential of this research could lead to not only better vaccines for influenza, which is potentially deadly in some patients and which has led to deaths during this year’s flu season, but also RSV.
RSV is a respiratory virus that infects the lungs and breathing passages. Most healthy people can recover from RSV infection in one to two weeks, but infections can be severe in young children, infants and older adults.
According to the Centers for Disease Control and Prevention, about 75,000 to 125,000 hospitalizations related to RSV occur among children under one year old, and RSV infection results in about 1.5 million outpatient medical visits among children under the age of five.
Kang’s lab will test VLP technology and ways to deliver the vaccines without long needles, such as nasal delivery, microneedles and oral vaccination.
Cold and Flu Season is Well Under Way But Don't Stifle a Sneeze Warn DoctorsNews
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors. One young man managed to rupture the back of his throat during this manoeuvre, leaving him barely able to speak or swallow, and in considerable pain.READ MORE
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Immunosuppressive Cells in Newborns Play Important Role in Controlling Inflammation in Early LifeNews
New research has characterized the transitory presence of myeloid-derived suppressor cells (MDSCs) in mouse and human newborns, revealing a critical role of these cells in regulation of inflammation in the early stages of life.READ MORE